What Is the Prognostic Impact of (11;14) in Myeloma?

By Blood Cancer Talks - Last Updated: October 20, 2023

In this episode of “Blood Cancer Talks,” the hosts are joined by Rafael Fonseca, MD and Martin Kaiser, MD to discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax treatment.

They also discuss the natural history of t(11;14) myeloma in the era of proteasome inhibitors and immunomodulatory imide drugs before launching into the efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis, the phase I/II trial on daratumumab-venetoclax-dexamethasone in relapsed or refractory myeloma, and the BELLINI and CANOVA trials.

Plus, they highlight some of the historical studies that identified t(11;14) and its prognostic impact in myeloma.

This podcast originally appeared on Blood Cancer Talks.

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Ayalew Tefferi, MD, on Career Development as a Clinician-Investigator

Angela Dispenzieri, MD, on Managing Newly Diagnosed AL Amyloidosis

ASH 2023 Myeloid Recap With Anand Patel, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

What Is the Prognostic Impact of (11;14) in Myeloma?

Related